Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Researchers are trying to find out more about the side effects of fremanezumab when treating
patients with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL) for migraine headaches.